Biomarkers: diagnostic highlights and surrogate end points

ISSN： 1462-2416

Source： Pharmacogenomics, Vol.5, Iss.5, 2004-07, pp. : 459-461

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The Impact of Biomarkers and Surrogate End Points on Regulatory Approval of New Drugs

Heart Drug, Vol. 2, Iss. 5, 2003-01 ,pp. : 235-245

Karger

Access to resources Recommend Favorite

Surrogate End Points of Antihypertensive Treatment: Left Ventricular Hypertrophy and Structural Alteration of Carotid Arteries

Heart Drug, Vol. 1, Iss. 2, 2004-11 ,pp. : 89-95

Karger

Access to resources Recommend Favorite

Diagnostic Biomarkers of Epilepsy

Current Pharmaceutical Biotechnology, Vol. 19, Iss. 6, 2018-05 ,pp. : 440-450

Bentham Science Publishers

Access to resources Recommend Favorite

Research Highlights: Highlights from the latest articles in essential tremor biomarkers and pharmacogenomics

By Agúndez José AG Jiménez-Jiménez Félix J Alonso-Navarro Hortensia García-Martín Elena

Pharmacogenomics, Vol. 14, Iss. 14, 2013-11 ,pp. : 1679-1682

Future Medicine

Access to resources Recommend Favorite

Thyroglobulin Autoantibodies as Surrogate Biomarkers in the Management of Patients with Differentiated Thyroid Carcinoma

Current Medicinal Chemistry, Vol. 21, Iss. 32, 2014-10 ,pp. : 3687-3692

Bentham Science Publishers

Access to resources Recommend Favorite